Tech Company Financing Transactions
SilkTech Biopharmaceuticals Funding Round
Skyview Ventures joined a $6.2 million Series A funding round for SilkTech Biopharmaceuticals. The funding round closed on 4/19/2019.
Transaction Overview
Company Name
Announced On
4/19/2019
Transaction Type
Venture Equity
Amount
$6,200,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to conduct the Phase 2 clinical trial and ongoing development work.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3700 Annapolis Ln. North 105
Plymouth, MN 55447
USA
Plymouth, MN 55447
USA
Phone
Website
Email Address
Overview
SilkTech Biopharmaceuticals is a clinical stage, privately-held company developing therapeutic drug products from our patented library of silk-derived protein (SDP) molecules. The company's lead drug product candidate is the SDP-4 eye drop which is in development for use in treating the signs and symptoms of Dry Eye Disease (DED).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Lawrence
VP - Operations
Jamie Christensen
VP - R & D
David Infanger
Browse more venture capital transactions:
Prev: 4/19/2019: Moveworks venture capital transaction
Next: 4/19/2019: Theator venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs